[1] Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol,2017,3(10):1335-1342. [2] Pathak S, Dash I, Taylor MR, et al. The surgical management of neuroendocrine tumour hepatic metastases. Eur J Surg Oncol,2013,39(3):224-228. [3] Meng XF, Pan YW, Wang ZB, et al. Primary hepatic neuroendocrine tumor case with a preoperative course of 26 years: a case report and literature review. World J Gastroenterol,2018,24(24):2640-2646. [4] Basuroy R, Bouvier C, Ramage JK, et al. Delays and routes to diagnosis of neuroendocrine tumours. BMC cancer,2018,18(1):1122. [5] 中华医学会病理学分会消化疾病学组. 中国胃肠胰神经内分泌肿瘤病理诊断共识(2020版). 中华病理学杂志,2021,50(1):14-20. [6] Yalav O, Ülkü A, Akçam TA, et al. Primary hepatic neuroendocrine tumor: Five cases with different preoperative diagnoses. Turk J Gastroenterol,2012,23(3):272-278. [7] Yang P, Huang X, Lai C, et al. SET domain containing 1B gene is mutated in primary hepatic neuroendocrine tumors. Int J Cancer,2019,145(11):2986-2995. [8] Zhang Z, Zhao X, Li Z, et al. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database. BMC Cancer,2021,21(1):567. [8] Han Y, Li L, Sun H. Computed tomography and magnetic resonance imaging in the diagnosis of primary neuroendocrine tumors of the liver. World Neurosurg,2020,138:723-731. [9] Shi C, Zhao Q, Dai B, et al. Primary hepatic neuroendocrine neoplasm: long-time surgical outcome and prognosis. Medicine(Baltimore),2018,97(31):e11764. [10] Shah D, Mandot A, Cerejo C, et al. The outcome of primary hepatic neuroendocrine tumors: a single-center experience. J Clin Exp Hepatol,2019,9(6):710-715. [11] Chatani PD, Aversa JG, McDonald JD, et al. Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors. Surgery,2021,170(1):106-113. [12] 王冬青, 曾蒙苏, 饶圣祥, 等. 原发性肝神经内分泌癌的影像表现.中华放射学杂志,2008,42(5):464-466. [13] 张文书, 赵婧, 纪元, 等. 肝原发性与转移性神经内分泌肿瘤的临床病理分析. 中华肝胆外科杂志,2012,18(03):161-165. [14] Jiao X, Luan W, Peng X, et al. Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors: a retrospective study. Medicine (Baltimore),2020,99(51):e23655. [15] 盛若凡, 解艳红, 纪元, 等. 肝脏神经内分泌肿瘤的磁共振成像特征及分级诊断. 中华肝胆外科杂志,2015,21(4):233-238. [16] 冯伟, 周梦豪, 张坦, 等. 原发性肝脏神经内分泌肿瘤21例临床特征和预后影响因素分析.中华肝胆外科杂志,2020,26(1):19-21. [17] Jung J, Hwang S, Hong SM, et al. Long-term postresection prognosis of primary neuroendocrine tumors of the liver.Ann Surg Treat Res,2019,97(4):176-183. [18] Wang HH, Liu ZC, Zhang G, et al. Clinical characteristics and outcome of primary hepatic neuroendocrine tumors after comprehensive therapy. World J Gastrointest Oncol,2020,12(9):1031-1043. [19] Kotteas EA, Syrigos KN, Saif MW. Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors. Onco Targets Ther,2016,9:699-704. [20] Qi Z, Tan H. Association between MGMT status and response to alkylating agents in patients with neuroendocrine neoplasms: a systematic review and meta-analysis. Biosci Rep,2020,40(3):BSR20194127. [21] Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol,2020,21(11):1500-1512. [22] Nikeghbalian S, Eshraghian A, Kazemi K, et al. Liver transplantation for high-grade primary hepatic neuroendocrine tumor with diffuse liver metastasis. J Gastrointest Cancer,2020,51(1):304-306. |